Navigation Links
New research network at McMaster aims to build a better eye
Date:9/24/2009

Researchers in Canada have established a new university/industry network to pursue the development of biomaterials, medical devices and drug delivery systems to treat the increasing incidence of eye disease.

The 20/20: NSERC Ophthalmic Materials Network (20/20 Network) has received $5 million as part of the Natural Sciences and Engineering Research Council of Canada (NSERC) funding announcement made by federal Minister of State (Science and Technology) Gary Goodyear today at McMaster University in Hamilton. Other funding is being provided by industrial and institutional partners, and the Ontario Centres of Excellence.

"Providing Canadians with a lifetime of perfect vision is the ultimate goal of the network," said Heather Sheardown, scientific director of the 20/20 Network and professor of chemical engineering at McMaster University. "It is rather ambitious but by combining different areas of expertise there is a lot of potential for drastically improving treatment of vision loss."

The 20/20 Network will focus on developing and commercializing new biomaterials, medical devices, and drug delivery devices for treating vision disorders. Some of the products being pursued include: composite and hybrid materials; ocular microgels, microemulsions and triggerable materials for drug release; a drug delivery system that attaches to the back of the eye to eliminate monthly needle injections; and contact lenses that eliminate end-of-day dryness and discomfort.

"The potential for new biomaterials and drug-delivery devices to address vision loss is hugely untapped," said Keith Gordon, vice president research, CNIB and chair of the Board of Directors of the 20/20 Network. "This is the type of initiative we need to release our research talent in Canada, provide new therapies for vision loss, and develop a homegrown industry."

The 12 researchers in the network are from four Canadian universities: McMaster University, where the administrative centre will be based, Queen's University, University of Toronto, and the University of Waterloo.

The 10 industrial partners are: Alimera Sciences, CIBA Vision Corporation, Custom Contact Lenses, Fovea Pharmaceuticals, iCo Therapeutics, Rimon Therapeutics, Siltech Corporation, Take Control Cosmedix, Vista Optics Limited, and Walsh Medical Devices.

It is estimated that 30 to 40 post-doctoral fellows, 35 to 45 graduate students and more than 60 summer students will be trained through the network over the five-year funding period.

"There is a lot of innovative and promising work being done in universities to address disorders of the eye and other conditions," said Michael May, president, Rimon Therapeutics Ltd. and a member of the board of directors. "This network provides an ideal forum to bring key players together and move solutions into the market as quickly as possible."


'/>"/>

Contact: Gene Nakonechny
genen@mcmaster.ca
905-525-9140 x26781
McMaster University
Source:Eurekalert

Related biology news :

1. WPI receives $1.3 million in federal awards for ongoing research in the life sciences
2. Stem cell applications and research highlight NJITs first Research Cafe
3. NIH announces 115 awards to encourage high-risk research and innovation
4. New genetic research indicates Jewish priesthood has multiple lineages
5. Prestigious $4.9 million NIH grant awarded to Case Western Reserve for colon cancer research
6. UNC scientists garner new NIH awards for high risk, transformative research
7. Researchers identify new brain pathway for regulating weight and bone mass
8. McGill garners 19 Canada Research Chairs and more than $17 million in funding
9. Research team finds first evolutionary branching for bilateral animals
10. 57 college presidents declare support for public access to publicly funded research in the US
11. Georgia State researcher to use $1 million grant to improve computer models for fighting wildfires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... 28, 2017 Summary This report ... Biochem and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/28/2017)... March 28, 2017  The National Pharmaceutical Council (NPC) ... health policy research organization as its newest member. ... Affairs ( North America ), will serve ... "We,re pleased to have Ipsen and Dr. ... Dan Leonard . "We welcome their insights in helping ...
(Date:3/28/2017)... -- Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or ... to treat cancers and other life-threatening conditions of the ... McGorry, CEO of Biostage, will present on the ... MassBio 2017 Annual Meeting on Thursday, March ... The 3D Printing and BioEngineering panel will ...
(Date:3/28/2017)... Focus is on the ... to the scientifically intensive operations of companies in ... and industrial. In today,s pre-market research, Stock-Callers.com dedicates attention ... PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera Therapeutics Inc. ... OCUL ). Learn more about these stocks ...
Breaking Biology Technology: